Sareum Holdings plc. has announced that it has entered into an initial 12-month collaborative agreement with Johnson & Johnson Pharmaceutical Research and Development (J&JPRD), a Division of Janssen Pharmaceutica N.V.
Under the terms of the agreement, Sareum will apply its skills in high throughput protein structure determination to assist J&JPRD scientists in developing new and improved therapeutics to help patients suffering from diseases of the central nervous system.
In return, Sareum will receive technology access fees and success dependent milestone payments.
Commenting on the agreement, Sareum’s Chief Executive Officer, Dr Tim Mitchell, said: “We are very excited to collaborate with J&JPRD and look forward to using our technology and expertise in this area to find new therapies for patients.”
Financial terms of the agreement were not disclosed.